|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
15581045 |
2004 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
|
10897039 |
2000 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
|
16865596 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
|
22302033 |
2012 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
|
16137437 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Immunophenotypic predictive profiling of BRCA1-associated breast cancer.
|
20941507 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Molecular profiling of single circulating tumor cells with diagnostic intention.
|
25358515 |
2014 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
|
19075277 |
2009 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Metastatic breast cancer: an updating.
|
16950593 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
|
12006526 |
2002 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.
|
21638049 |
2012 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
|
16596621 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Mouse breast cancer model-dependent changes in metabolic syndrome-associated phenotypes caused by maternal dioxin exposure and dietary fat.
|
18840765 |
2009 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
|
20197467 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.
|
15970926 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
|
16978400 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
[Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer].
|
18819904 |
2008 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
|
16682728 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
|
16091755 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
|
17614302 |
2007 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
15581045 |
2004 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
|
16495393 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation.
|
19617202 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
12655533 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
|
11248153 |
2001 |